AdaptHealth (AHCO) Expected to Announce Quarterly Earnings on Tuesday

AdaptHealth (NASDAQ:AHCO) is anticipated to issue its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.34 per share and revenue of $832.5060 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

AdaptHealth Trading Up 1.1%

AHCO stock opened at $10.20 on Tuesday. The company has a market capitalization of $1.38 billion, a PE ratio of 18.55, a price-to-earnings-growth ratio of 1.16 and a beta of 1.72. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.86 and a current ratio of 1.08. AdaptHealth has a one year low of $7.11 and a one year high of $11.63. The company’s 50 day moving average price is $10.25 and its two-hundred day moving average price is $9.64.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Zacks Research raised AdaptHealth from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Canaccord Genuity Group boosted their price objective on AdaptHealth from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Wall Street Zen cut shares of AdaptHealth from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Weiss Ratings upgraded shares of AdaptHealth from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, January 30th. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.25.

Insider Activity

In related news, Director David Solomon Williams III sold 5,000 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $9.43, for a total value of $47,150.00. Following the completion of the transaction, the director directly owned 45,045 shares of the company’s stock, valued at $424,774.35. This represents a 9.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.55% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. lifted its stake in shares of AdaptHealth by 22.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,003 shares of the company’s stock valued at $70,000 after purchasing an additional 1,279 shares during the period. Tower Research Capital LLC TRC grew its stake in AdaptHealth by 318.0% in the second quarter. Tower Research Capital LLC TRC now owns 9,592 shares of the company’s stock worth $90,000 after purchasing an additional 7,297 shares during the period. Tidal Investments LLC bought a new position in AdaptHealth in the second quarter worth $96,000. CIBC Bancorp USA Inc. purchased a new position in AdaptHealth during the third quarter valued at $97,000. Finally, Prelude Capital Management LLC bought a new stake in shares of AdaptHealth during the 3rd quarter valued at $102,000. Hedge funds and other institutional investors own 82.67% of the company’s stock.

AdaptHealth Company Profile

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.